– USA, MA – Lumeon, the leader in care journey orchestration, today announced the appointment of Tom Zajac to its Board of Directors as executive chair, effective December 20, 2020, supporting its continued growth in helping healthcare systems develop and scale new models of delivery.
“We are pleased to welcome Tom Zajac to the Lumeon board,” said Founder and CEO, Robbie Hughes. “Tom’s deep experience in healthcare transformation, having built and led multiple public and private healthcare technology companies through rapid growth, delivering patient-centered outcomes and industry-leading customer satisfaction, will be invaluable to Lumeon as we continue to grow our business and pursue our mission to ensure the safe, scalable delivery of the right care to the right patient, every time.”
Dr. Carl Schramm, who will be stepping down as board chair commented, “Although we began our search looking for a non-executive healthcare leader to strengthen the board, it became clear the value Tom would bring working in closer partnership with the management team in building out the future of the company. The best way I saw to accomplish this was to allow him to do what he does best – help to guide companies to rapidly achieve scale as executive chair.”
Dr. Carl Schramm will continue as an advisor to the company and work with the board and management team to develop the strategic direction of the business.
The appointment follows Lumeon’s $30M Series D funding, announced in July and led by Optum Ventures.
“With the closing of Lumeon’s Series D funding round and the success that the company is seeing in the US market, Tom’s appointment is further testament to the execution of the company’s vision,” said Dr. Ash Patel of Optum Ventures. “Tom’s track record of building companies and developing entire markets will be important as Lumeon continues to scale up operations.”
About Tom Zajac
Tom Zajac previously served as CEO of Population Health at Philips, president, and CEO of Wellcentive, chief customer officer at Elsevier, and CEO of CareScience. He is a senior scholar in the Jefferson School of Population Health, and a board member and advisor for several health technology companies.
“Lumeon sits at a critical intersection in healthcare’s new normal – empowering and engaging patients to get the best possible care, streamlining the care process to optimize critical care team resources, and reducing variation and cost for strained provider financials,” said Tom Zajac. “The Lumeon team is purpose-driven, and I am excited to support both the growth of the company and its mission of empowering and driving better care.”
Lumeon’s solutions help healthcare providers synchronize care delivery and engage patients anywhere – virtually, at home, or in facilities – by automating care coordination and engagement at scale. Over 70 customers across 12 countries have documented success improving care quality and outcomes, reducing cost, and alleviating workload on overburdened clinical teams.
About Lumeon
Lumeon’s care journey orchestration platform helps health systems scale efficient, effective care delivery both within and beyond their hospitals’ four walls.
Lumeon’s industry-leading solutions address the needs of patient access, surgery, population health, amongst many others. They transform the EHR into an agile care delivery platform that navigates the patient along with a personalized, adaptive care plan, coordinating the care team to deliver the right care, at the right time, every time. At every step along the journey, they harmonize care, communication, tasks, and decisions to increase compliance and productivity, free up capacity, and deliver superior outcomes at a reduced cost.
More than 70 health systems across 12 countries have deployed Lumeon’s multi-award-winning platform.
For more information: https://www.lumeon.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
